STOCK TITAN

Nasdaq warns Dyadic (NASDAQ: DYAI) over bid price and listing shortfalls

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Dyadic International, Inc. reports it has received a Nasdaq notification starting a process that could lead to delisting because its share price has stayed below the $1.00 minimum required by Nasdaq Listing Rule 5450(a)(1), known as the Bid Price Rule.

As of June 17, 2026, Dyadic had not regained compliance or met the $5 million shareholders’ equity level needed for an extension. The notice also cites noncompliance with Nasdaq Listing Rule 5550(b), which requires at least $2.5 million in shareholders’ equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.

The company plans to request a hearing before an independent Nasdaq panel, which will temporarily halt any suspension or delisting action. Under Nasdaq rules, the latest possible deadline for Dyadic to regain full compliance is December 15, 2026, but there is no assurance it will succeed or avoid delisting.

Positive

  • None.

Negative

  • Nasdaq delisting process initiated: Dyadic has received a Nasdaq notice starting a process that could result in delisting, after failing the $1.00 Bid Price Rule and separate continued listing standards, creating significant risk to its Nasdaq listing and potentially to liquidity and future capital access.

Insights

Nasdaq has begun a delisting process for Dyadic over price and listing standard failures.

Dyadic International has been notified that Nasdaq has started a process that could end in delisting because its stock has not met the $1.00 Bid Price Rule and it also fails separate continued listing standards tied to equity, market value, or net income.

The company plans to request a hearing before an independent Nasdaq panel, which pauses delisting while the matter is reviewed. The panel can grant additional time, but only up to December 15, 2026, and there is no assurance Dyadic will regain compliance or keep its listing.

If Dyadic ultimately loses its Nasdaq listing, trading could move to a less liquid market and access to capital could become more constrained. The outcome will depend on the company’s ability to improve its share price and financial metrics before the Nasdaq deadlines.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Minimum bid price $1.00 per share Nasdaq Listing Rule 5450(a)(1) Bid Price Rule
Shareholders’ equity threshold for extension $5 million Condition for additional 180-day bid price cure period
Shareholders’ equity continued listing minimum $2.5 million One of Nasdaq Listing Rule 5550(b) tests
Market value of listed securities test $35 million Alternative Nasdaq Listing Rule 5550(b) standard
Net income continued listing test $500,000 Net income from continuing operations requirement
Initial bid price cure period end June 17, 2026 End of first 180-day Bid Price Rule period
Maximum compliance deadline December 15, 2026 Latest date panel can grant for full compliance
Bid Price Rule regulatory
"failure to comply with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”)"
Nasdaq Listing Rule 5550(b) regulatory
"failure to comply with the separate Nasdaq Listing Rule 5550(b), which requires it to meet"
A Nasdaq listing rule that requires companies on the Nasdaq Capital Market to keep their share price at or above a minimum level (commonly $1.00 per share) to avoid delisting. It matters to investors because dropping below that threshold can start a formal review that may remove a stock from the exchange, which can reduce trading liquidity, make shares harder to sell, and hurt a company’s ability to raise capital — similar to a store losing its grade and being forced to close or move to a less prominent location.
Continued Listing Standards regulatory
"net income from continuing operations (the “Continued Listing Standards”). As previously disclosed"
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.
Nasdaq hearings panel regulatory
"the Company plans to request a hearing before an independent Nasdaq hearings panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of Section 27A of the Securities Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001213809 0001213809 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): June 18, 2026

 

 

 

 

Dyadic International, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32513   45-0486747

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

1044 North U.S. Highway One, Suite 201

Jupiter, FL 33477

(Address of principal executive offices and zip code)

 

(561) 743-8333

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   DYAI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

(a)

 

On June 18, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has initiated a process that could result in the delisting of the Company’s securities from Nasdaq due to the Company’s failure to comply with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), which requires listed companies to maintain a minimum bid price of $1.00 per share. As previously disclosed, in accordance with the Bid Price Rule, the Company was provided 180 calendar days, or until June 17, 2026, to regain compliance with the Bid Price Rule. The Company would be eligible for an additional 180 calendar days (until December 15, 2026) to cure the deficiency under the Bid Price Rule if it achieved, among other things, the applicable market value of publicly held shares requirement for continued listing and applicable standards for initial listing on the Nasdaq Capital Market, including shareholders’ equity of $5 million. As of June 17, 2026, the Company had neither regained compliance with the Bid Price Rule nor met the condition for an extension by having shareholders’ equity of at least $5 million.

 

The Notification also cites the Company’s failure to comply with the separate Nasdaq Listing Rule 5550(b), which requires it to meet any of the following minimum conditions: $2.5 million in shareholders’ equity; $35 million in market value of listed securities; or $500,000 of net income from continuing operations (the “Continued Listing Standards”). As previously disclosed, the Company initially had until September 23, 2026 to regain compliance with the Continuing Listing Standards. However, given that the Company is now subject to delisting proceedings for the Bid Price Rule deficiency, its Continued Listing Standards deficiency serves as an additional basis for delisting of the Company’s securities from The Nasdaq Stock Market.

 

In response to the above, the Company plans to request a hearing before an independent Nasdaq hearings panel (the “Panel”). The hearing request automatically stays any suspension or delisting action at least through the date of the written panel decision. The Company may determine to take steps to cure the deficiencies under the Bid Price Rule and the Continuing Listing Standards prior to the date of the hearing by the Panel. To the extent the Company does not or is unable to take those steps, or the Panel determines to hear the Company’s matter regardless of any cure by the Company prior to the hearing date, the Company may determine to seek at the Panel, subject to the Panel’s discretion, an extension to regain compliance with the Bid Price Rule and the Continued Listing Standards. Pursuant to the relevant Nasdaq Listing Rules, the maximum amount of time that can be granted by the Panel for compliance with the Bid Price Rule and Continuing Listing Standards runs through December 15, 2026.

 

Despite the efforts described above, there can be no assurance that the Company will ultimately regain compliance with all applicable requirements for continued listing, that the Panel will grant the Company a further extension to the extent requested by the Company, or that the Panel will determine to avoid delisting the Company following any cure of the relevant deficiencies. An adverse Panel decision may also be eligible for a further appeal to the Nasdaq Listing and Hearing Review Council. For more information on the delisting process and the consequences of any adverse determination by the Panel, see “If we fail to comply with listing standards of the Nasdaq Stock Market LLC (“Nasdaq”), our common stock may be delisted, adversely affecting the liquidity and market price of our common stock, as well as our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern.” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission on March 25, 2026, as amended on April 30, 2026.

 

Safe Harbor Regarding Forward-Looking Statements

 

This current report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words “expect,” “should,” intend,” anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” or other similar terms or variations of them. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) our ability to comply with the listing standards of the Nasdaq. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 18, 2026

 

  Dyadic International, Inc.
     
  By: /s/ Ping Rawson
  Name: Ping Rawson
  Title: Chief Financial Officer

 

 

 

FAQ

Why did Dyadic International (DYAI) receive a Nasdaq delisting notice?

Dyadic received a Nasdaq notice because its stock failed to meet the $1.00 minimum bid price required by Listing Rule 5450(a)(1). It also does not meet separate continued listing standards tied to shareholders’ equity, market value of listed securities, or net income from continuing operations.

What Nasdaq listing standards is Dyadic International (DYAI) currently failing?

Dyadic is not in compliance with the Bid Price Rule requiring a $1.00 minimum bid and Nasdaq Listing Rule 5550(b). That rule requires either $2.5 million in shareholders’ equity, $35 million market value of listed securities, or $500,000 net income from continuing operations.

How long does Dyadic International (DYAI) have to regain Nasdaq compliance?

Under Nasdaq rules, the maximum period the panel can grant Dyadic to regain compliance with the Bid Price Rule and continued listing standards runs through December 15, 2026. Any extension and the final outcome depend on the independent Nasdaq hearings panel’s decisions.

What steps is Dyadic International (DYAI) taking in response to the Nasdaq notice?

Dyadic plans to request a hearing before an independent Nasdaq hearings panel. This hearing request automatically stays any suspension or delisting at least until the panel issues its written decision, while the company considers measures to cure its bid price and listing standard deficiencies.

Could Dyadic International (DYAI) still avoid being delisted from Nasdaq?

Dyadic may avoid delisting if it successfully cures its bid price and continued listing standard deficiencies within allowed timeframes. However, the company states there is no assurance it will regain full compliance or that the Nasdaq panel will decide against delisting after its review.

What financial thresholds are relevant to Dyadic International’s Nasdaq listing risk?

Key thresholds include a $1.00 minimum bid price, $5 million shareholders’ equity for a prior extension, and continued listing options of at least $2.5 million equity, $35 million market value of listed securities, or $500,000 net income from continuing operations.

Filing Exhibits & Attachments

3 documents